News: Umeå, 9 August 2022.  Lipum (publ), a biopharmaceutical company focused on chronic inflammatory diseases, today announced its participation in the following upcoming conferences.

LSX Nordic, Copenhagen, Denmark, 6-7 September             

Biostock Investerarevent, digital, 14 September

Nordic Life Science Days, Malmö, Sweden, 28-29 September

Bio-Europe, Leipzig, Germany, 24-26 October

Redeye Life Science Day, Stockholm, Sweden, 24 November

Biostock Life Science Summit, Lund, Sweden, 29-30 November

“I am looking forward to these events. We are approaching clinical trials of our biological lead candidate SOL-116 and industry meetings provide good opportunities to present our progress”, says CEO Einar Pontén.

For further information, please contact:
Einar Pontén, CEO
Mobil:     +46 70 578 34 95

About Lipum
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email:, phone: +46 8 503 000 50.